KRAS: A Druggable Target in Colon Cancer Patients

KRAS: A Druggable Target in Colon Cancer Patients

Mutations in <i>KRAS</i> are among the most frequent aberrations in cancer, including colon cancer. KRAS direct targeting is daunting due to KRAS protein resistance to small molecule inhibition. Moreover, its elevated affinity to cellular guanosine triphosphate (GTP) has made the design...

Full description

Bibliographic Details
Main Authors: Francesca Negri, Lorena Bottarelli, Gian Luigi de’Angelis, Letizia Gnetti
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:International Journal of Molecular Sciences
Subjects:
<i>KRAS</i> oncogene
RAS pathway
colon cancer
targeted therapy
sotorasib
adagrasib
Online Access:https://www.mdpi.com/1422-0067/23/8/4120

Internet

https://www.mdpi.com/1422-0067/23/8/4120

Similar Items